The same physician list, budget, creative, flight dates, and bid strategy should produce roughly the same reach, right? A recent specialty pharma test suggests otherwise. The test found 32% greater unique physician reach when the same deterministic audience was activated using supply-side targeting. The test also raises a bigger question about HCP audience targeting: How much does the technology behind audience activation affect the number of physicians a campaign can actually reach?
Table of Contents
- Why the 32% physician reach difference matters
- How identity resolution affects HCP targeting
- Why the supply path can change campaign performance
- What pharma media buyers should examine
- Conclusion
- FAQs
Why the 32% Physician Reach Difference Matters
Pharma marketers spend significant time building precise physician target lists. Specialty, prescribing behavior, diagnosis patterns, claims data, and other signals can all help determine which healthcare professionals matter most. However, defining the right audience is only the beginning.
A controlled test announced by Wrango and OpenX in August 2026 offers a useful example. According to OpenX’s report on the test, multiple specialty pharma campaigns compared different activation paths for the same deterministic HCP audience.
Importantly, creative, budgets, flight dates, and bid strategies were held constant. Yet OpenXSelect supply-side targeting produced a 32% increase in unique physician reach on identical budgets.
That difference matters because reach is a core part of HCP campaign economics. If one activation method reaches more physicians without requiring additional budget, the value of the media plan changes considerably.
Moreover, the test reported a 22% lower cost per unique HCP for OpenXSelect under open targeting. The DSP-direct path also concentrated impressions among fewer physicians. Therefore, higher frequency did not necessarily indicate stronger campaign coverage. Instead, it could mean the campaign was repeatedly reaching HCPs who were easier to identify.
This distinction is especially important for narrow specialty audiences. When the addressable physician pool is small, repeatedly serving ads to already matched doctors can quickly create diminishing returns.
How Identity Resolution Changes HCP Audience Targeting
Modern HCP targeting depends on connecting known healthcare professionals with identifiers that can be recognized during digital media transactions.
A deterministic target list may begin with strong data, including NPI-linked physician records or other verified professional information. However, that does not guarantee every eligible physician remains identifiable throughout the media supply chain.
Think of it like having an accurate guest list but an unreliable check-in system. You know exactly who should enter, yet some guests may never be recognized when they arrive.
That is where identity resolution becomes important.
In the Wrango and OpenX test, OpenXSelect applied a multi-signal identity resolution waterfall at the point of the bid request. In simple terms, the system could evaluate multiple available signals closer to the media opportunity rather than depending on a single upstream match.
Consequently, marketers should distinguish audience definition from audience activation. A highly accurate HCP list can still underperform when the activation layer recognizes only part of it.
This issue is becoming more important as healthcare marketers operate across fragmented devices, browsers, publishers, and privacy-focused environments. Veeva’s HCP Reach Segments, for example, reflects the industry’s growing emphasis on activating clinically relevant HCP audiences across DSPs, publishers, social platforms, audio, television, and other channels.
The practical lesson is straightforward. Marketers should evaluate an HCP targeting strategy not only by who is on the list, but also by how reliably those physicians can be recognized when an impression becomes available.
Why Supply-Path Architecture Can Affect HCP Reach
One possible explanation for a reach difference might be access to more publishers. However, the controlled test produced a particularly interesting result.
According to OpenX, 100% of impressions delivered through the DSP-direct path appeared on publishers that were also accessible through the SSP Deal ID path. Therefore, the reported reach gain was not attributed to an entirely different publisher ecosystem.
Instead, the results point toward identity resolution and activation methodology as key variables.
That finding changes how pharma marketers may need to evaluate programmatic campaigns. Traditionally, teams may focus on the target list, CPM, inventory quality, viewability, frequency, and total impressions. Those metrics remain important. However, they do not fully reveal how much of the intended HCP audience is technically addressable.
Supply-path decisions can influence when and where identity signals are available. As a result, two campaigns using the same audience data can potentially produce different reachable populations.
Pharma marketers already recognize the value of deterministic targeting. Pharma Marketing Network’s guide to HCP targeting in pharma marketing discusses the role of prescribing data, EHR information, real-world data, CRM inputs, and other signals in building useful HCP segments.
The next question should be what happens after those segments are built.
Platforms and exchanges can use different identity technologies and activation approaches. For example, eHealthcare Solutions provides digital advertising and programmatic targeting capabilities focused on healthcare and pharma audiences. Understanding how partners resolve and activate HCP identity can therefore become part of media partner evaluation rather than a technical detail left entirely behind the scenes.
What Pharma Media Buyers Should Examine Next
For media buyers, the test does not mean every supply-side activation will automatically generate a 32% improvement. Results from one controlled test should not be treated as a universal benchmark. Instead, the finding provides a strong reason to test infrastructure as carefully as audience data.
Start with unique HCP reach. Marketers should know how many physicians from the intended target list were actually reached during a meaningful measurement window.
Next, examine cost per unique HCP alongside CPM and total impressions. A low CPM can look efficient while hiding heavy frequency against a limited group of physicians. Conversely, reaching more unique target HCPs may provide greater strategic value even when conventional delivery metrics look similar.
Teams should also ask partners how identity resolution works. Is activation dependent on one identifier, or can multiple privacy-compliant signals be used? Where does matching occur? How much of the original deterministic audience remains addressable when a bid request reaches the buying platform?
Furthermore, frequency should be interpreted in context. High frequency may be intentional for some campaigns. However, when frequency rises because only a small share of the target list can be matched, it can signal an activation problem.
Finally, pharma brands can run controlled tests of their own. Keep the audience, creative, budget, bidding strategy, and campaign dates consistent while changing the activation path. Then compare unique HCP reach, frequency distribution, cost per reached physician, and other agreed performance measures.
That approach makes the infrastructure behind HCP targeting measurable rather than theoretical.
Conclusion
The 32% reach result highlights a simple but important idea: having the right HCP list does not guarantee that every physician on it is equally reachable.
Identity resolution and supply-path architecture can influence how much of a deterministic audience becomes addressable during real media transactions. Consequently, pharma marketers may need to evaluate activation infrastructure with the same attention they already give audience quality, inventory, and measurement.
Better HCP targeting is not simply about adding more data. Increasingly, it is about preserving useful identity signals from the target list to the impression opportunity.
For media buyers, that creates a practical next step. Test the path, measure unique physicians reached, examine frequency concentration, and ask vendors to explain exactly how audience identity survives activation. The audience may be the same, but as this test suggests, the reachable audience may not be.
FAQs
What is HCP audience targeting?
HCP audience targeting is the process of identifying and reaching healthcare professionals based on factors such as specialty, prescribing behavior, professional identity, clinical activity, or other relevant criteria.
Why can the same HCP list produce different reach?
Different activation systems may resolve physician identities differently. Therefore, one platform or supply path may recognize more members of the same deterministic target list during media transactions.
Does higher ad frequency mean better HCP campaign performance?
Not necessarily. Higher frequency can reflect a deliberate messaging strategy, but it can also occur when impressions are concentrated among a smaller number of matched physicians. Marketers should evaluate frequency alongside unique HCP reach.
Should pharma marketers use supply-side targeting?
Supply-side targeting can be worth testing when it offers strong identity resolution and appropriate inventory controls. However, marketers should validate performance through controlled comparisons rather than assume one activation method will always outperform another.
Which metrics can help evaluate HCP targeting infrastructure?
Unique HCP reach, cost per unique HCP, match or addressability rates, frequency distribution, target-list penetration, inventory quality, and downstream outcomes can provide a more complete picture than impressions or CPM alone.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
